openPR Logo
Press release

Investigation announced for Investors in shares of Athenex, Inc. (NASDAQ: ATNX)

05-20-2021 11:03 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Athenex, Inc. (NASDAQ: ATNX) shares.

An investigation on behalf of current long term investors in Athenex, Inc. (NASDAQ: ATNX) shares.

Certain directors of Athenex Inc. are under investigation over potential breaches of fiduciary duties.

Investors who are current long term investors in Athenex, Inc. (NASDAQ: ATNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: ATNX stocks follows a lawsuit filed against Athenex, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ATNX stocks, concerns whether certain Athenex directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Western District of New York the plaintiff alleges that, the Defendants failed to disclose to investors that the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae, that the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR, that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR, that the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial, that as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form, and that as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Athenex, Inc. (NASDAQ: ATNX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Athenex, Inc. (NASDAQ: ATNX) here

News-ID: 2287758 • Views:

More Releases from Shareholders Foundation

Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to recover losses
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover losses
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc.. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV
Investigation announced for Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) over possible Violations of Securities Laws
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Athenex

Sodium Bicarbonate Injection Market Recovery and Impact Analysis Report | Amphas …
The latest market research report released by SMI, on the Global "Sodium Bicarbonate Injection Market 2022" is segmented by region (country), company, and Application. It can declare the latest updates and powerful insights on the Sodium Bicarbonate Injection industry to help you improve your business strategy and ensure strong revenue growth for years to come. The report provides a valuable resource for market participants, investors, business stakeholders, and new entrants
Doxorubicin Injection Market 2021 Healthcare, Clinical Reviews, Survey Reports- …
The “Doxorubicin Injection Market” report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from industry experts and professionals. The study is a detailed document on key aspects of the markets including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis. The report is updated with
U.S. Compounding Pharmacies Market By Industry Players B. Braun, Fagron, Athenex …
U.S. Compounding Pharmacies Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges. Large number of patients increasingly preferring prescription drugs may augment the U.S. compounding market growth. Compounded bioidentical menopausal hormone drugs are gaining grip among women in the
Deadline on May 3rd coming up in Lawsuit for Investors in Athenex, Inc. (NASDAQ: …
A deadline is coming up on May 3, 2021 in the lawsuit filed for certain investors of Athenex, Inc. (NASDAQ: ATNX) over alleged securities laws violations by Athenex, Inc. Investors who purchased shares of Athenex, Inc. (NASDAQ: ATNX) have certain options and there are strict and short deadlines running. Deadline: May 3, 2021. NASDAQ: ATNX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Lawsuit filed for Investors in shares of Athenex, Inc. (NASDAQ: ATNX)
An investor, who purchased shares of Athenex, Inc. (NASDAQ: ATNX), filed a lawsuit over alleged violations of Federal Securities Laws by Athenex, Inc. Investors who purchased shares of Athenex, Inc. (NASDAQ: ATNX) have certain options and for certain investors are short and strict deadlines running. Deadline: May 3, 2021. NASDAQ: ATNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Buffalo, NY based Athenex, Inc., a biopharmaceutical
Investigation for Investors in Athenex, Inc. (NASDAQ: ATNX) over possible Violat …
Athenex, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Athenex, Inc. (NASDAQ: ATNX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Athenex, Inc. regarding its business, its prospects and its operations were materially false and misleading at